These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 20522814)

  • 1. Protective effect of high-density lipoprotein-based therapy in a model of embolic stroke.
    Lapergue B; Moreno JA; Dang BQ; Coutard M; Delbosc S; Raphaeli G; Auge N; Klein I; Mazighi M; Michel JB; Amarenco P; Meilhac O
    Stroke; 2010 Jul; 41(7):1536-42. PubMed ID: 20522814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-density lipoprotein-based therapy reduces the hemorrhagic complications associated with tissue plasminogen activator treatment in experimental stroke.
    Lapergue B; Dang BQ; Desilles JP; Ortiz-Munoz G; Delbosc S; Loyau S; Louedec L; Couraud PO; Mazighi M; Michel JB; Meilhac O; Amarenco P
    Stroke; 2013 Mar; 44(3):699-707. PubMed ID: 23422087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke.
    Zhang L; Zhang ZG; Zhang RL; Lu M; Krams M; Chopp M
    Stroke; 2003 Jul; 34(7):1790-5. PubMed ID: 12805500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of postischemic thrombolysis with or without neuroprotection in a focal embolic model of cerebral ischemia.
    Yang Y; Li Q; Miyashita H; Howlett W; Siddiqui M; Shuaib A
    J Neurosurg; 2000 May; 92(5):841-7. PubMed ID: 10794299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination treatment with VELCADE and low-dose tissue plasminogen activator provides potent neuroprotection in aged rats after embolic focal ischemia.
    Zhang L; Zhang ZG; Buller B; Jiang J; Jiang Y; Zhao D; Liu X; Morris D; Chopp M
    Stroke; 2010 May; 41(5):1001-7. PubMed ID: 20203318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination treatment with low-dose Niaspan and tissue plasminogen activator provides neuroprotection after embolic stroke in rats.
    Shehadah A; Chen J; Cui Y; Zhang L; Roberts C; Lu M; Chopp M
    J Neurol Sci; 2011 Oct; 309(1-2):96-101. PubMed ID: 21802695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simvastatin reduced ischemic brain injury and perfusion deficits in an embolic model of stroke.
    Shabanzadeh AP; Shuaib A; Wang CX
    Brain Res; 2005 Apr; 1042(1):1-5. PubMed ID: 15823246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat.
    Zhang L; Zhang ZG; Ding GL; Jiang Q; Liu X; Meng H; Hozeska A; Zhang C; Li L; Morris D; Zhang RL; Lu M; Chopp M
    Circulation; 2005 Nov; 112(22):3486-94. PubMed ID: 16316970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain proteomics identifies potential simvastatin targets in acute phase of stroke in a rat embolic model.
    Campos-Martorell M; Salvador N; Monge M; Canals F; García-Bonilla L; Hernández-Guillamon M; Ayuso MI; Chacón P; Rosell A; Alcazar A; Montaner J
    J Neurochem; 2014 Jul; 130(2):301-12. PubMed ID: 24661059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of Neuroprotective Effects of High-Density Lipoprotein Therapy in Stroke under Acute Hyperglycemic Conditions.
    Couret D; Planesse C; Patche J; Diotel N; Nativel B; Bourane S; Meilhac O
    Molecules; 2021 Oct; 26(21):. PubMed ID: 34770774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granulocyte-colony stimulating factor delays PWI/DWI mismatch evolution and reduces final infarct volume in permanent-suture and embolic focal cerebral ischemia models in the rat.
    Bråtane BT; Bouley J; Schneider A; Bastan B; Henninger N; Fisher M
    Stroke; 2009 Sep; 40(9):3102-6. PubMed ID: 19644069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective effect of SolCD39, a novel platelet aggregation inhibitor, on transient middle cerebral artery occlusion in rats.
    Belayev L; Khoutorova L; Deisher TA; Belayev A; Busto R; Zhang Y; Zhao W; Ginsberg MD
    Stroke; 2003 Mar; 34(3):758-63. PubMed ID: 12624304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced brain infarct volume and improved neurological outcome by inhibition of the NR2B subunit of NMDA receptors by using CP101,606-27 alone and in combination with rt-PA in a thromboembolic stroke model in rats.
    Yang Y; Li Q; Yang T; Hussain M; Shuaib A
    J Neurosurg; 2003 Feb; 98(2):397-403. PubMed ID: 12593629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ebselen, a seleno-organic antioxidant, is neuroprotective after embolic strokes in rabbits: synergism with low-dose tissue plasminogen activator.
    Lapchak PA; Zivin JA
    Stroke; 2003 Aug; 34(8):2013-8. PubMed ID: 12855833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. THR-18, a 18-mer peptide derived from PAI-1, is neuroprotective and improves thrombolysis by tPA in rat stroke models.
    Krakovsky M; Polianski V; Nimrod A; Higazi A; Leker RR; Lamensdorf I
    Neurol Res; 2011 Nov; 33(9):983-90. PubMed ID: 22081002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy of rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, and NMDA receptor antagonist (MK-801) on experimental embolic stroke in rats.
    Allahtavakoli M; Shabanzadeh A; Roohbakhsh A; Pourshanazari A
    Basic Clin Pharmacol Toxicol; 2007 Nov; 101(5):309-14. PubMed ID: 17910613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The proteasome inhibitor VELCADE reduces infarction in rat models of focal cerebral ischemia.
    Henninger N; Sicard KM; Bouley J; Fisher M; Stagliano NE
    Neurosci Lett; 2006 May; 398(3):300-5. PubMed ID: 16490315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suramin reduces infarct volume in a model of focal brain ischemia in rats.
    Kharlamov A; Jones SC; Kim DK
    Exp Brain Res; 2002 Dec; 147(3):353-9. PubMed ID: 12428143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed post ischemic treatment with Rosiglitazone attenuates infarct volume, neurological deficits and neutrophilia after embolic stroke in rat.
    Allahtavakoli M; Moloudi R; Arababadi MK; Shamsizadeh A; Javanmardi K
    Brain Res; 2009 May; 1271():121-7. PubMed ID: 19332033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of albumin prior to delayed thrombolysis reduces brain edema and blood brain barrier permeability in an embolic stroke model.
    Lu HT; Zhao JG; Li MH; Li YD
    Brain Res; 2012 Feb; 1438():75-84. PubMed ID: 22227456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.